Peer-reviewedLicence not statedHypertension (Dallas, Tex. : 1979)
HuR inhibition attenuates hypertension and fibrosis in chronic kidney disease
4 affiliations
- 1Division of Nephrology & Hypertension, Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, USA.
- 2Department of Nutrition and Integrative Physiology and Molecular Medicine Program, University of Utah, Salt Lake City, UT, USA.
- 3Department of Chemical Biology and Medical Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
- 4Department of Molecular Biosciences, University of Kansas, Lawrence, KS, USA.
Related
- Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease.
- Enhancer of Zeste Homolog 2 Inhibition Attenuates Atrial Fibrillation Post-Myocardial Infarction Through Reduced Atrial Fibrosis
- Group IVA Cytosolic Phospholipase A2 (cPLA2α): Pharmacological Inhibition Attenuates Kidney Inflammation and Fibrosis
- Dapagliflozin Attenuates Post-Infarction Myocardial Fibrosis Associated With the Inhibition of NLRP3-Dependent Inflammation
- Physical activity attenuates mortality risk associated with elevated resting heart rate in chronic kidney disease
BibTeX
@article{zhuang2026inhibition,
title = {{HuR inhibition attenuates hypertension and fibrosis in chronic kidney disease}},
author = {Lili Zhuang and Zhou Wang and Ziwei Fu and Sohom Mookherjee M. and J. David Symons and Jeffrey Aube and Xiaoqing Wu and Liang Xu and Yufeng Huang},
journal = {Hypertension (Dallas, Tex. : 1979)},
year = {2026},
month = nov,
doi = {10.1161/hypertensionaha.126.26933},
url = {https://doi.org/10.1161/hypertensionaha.126.26933},
}
RIS
TY - JOUR
TI - HuR inhibition attenuates hypertension and fibrosis in chronic kidney disease
AU - Lili Zhuang
AU - Zhou Wang
AU - Ziwei Fu
AU - Sohom Mookherjee M.
AU - J. David Symons
AU - Jeffrey Aube
AU - Xiaoqing Wu
AU - Liang Xu
AU - Yufeng Huang
PY - 2026
DA - 2026/11/10
JO - Hypertension (Dallas, Tex. : 1979)
DO - 10.1161/hypertensionaha.126.26933
UR - https://doi.org/10.1161/hypertensionaha.126.26933
SN - 0194-911X
SN - 1524-4563
ER -